Loading patent…
AssigneeNew York Blood Center, Inc.
InventorsBernard Horowitz, Jay E. Valinsky, Nicholas E. Geacintov, Bolanle Williams, Shanti B. Rywkin
Estimating the term…
The present invention concerns a method of inactivating extracelluar lipid enveloped human pathogenic virus or intracelular human pathogenic virus in a blood cell-containing composition without incurring substantial disruption or inactivation of cells, comprising contacting a cell-containing composition having .gtoreq.1.times.10.sup.9 cells/ml and containing infectious virus with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer to substantially inactivate the virus to effect a virus kill of at least 10.sup.4 and to result in a retention of intact cell functionality and structure of greater than 80%. The present invention also is directed to a composition comprising human red blood cells suitable for transfusion at a concentration of .gtoreq.1.times.10.sup.9 cells/ml and having all extracellular lipid enveloped and intracellular human pathogenic viruses in a non-infectious form.
A process for treating a blood cell-containing composition in order to inactivate any extracellular lipid enveloped human pathogenic virus and intracellular human pathogenic virus contained therein without incurring substantial disruption or inactivation of the cells, comprising contacting the cell-containing composition having .gtoreq.1.times.10.sup.9 cells/ml with a virucidally effective amount of at least one photodynamically active compound having an absorption maximum of .gtoreq.630 nm, with light and with oxygen to substantially inactivate said virus if present therein and to effect a virus kill of at least 10 .sup.4 and to result in a retention of intact cell functionality and structure of greater than 80%.
A process according to clam 1, wherein the cell-containing composition has 50 to 60 mg/ml protein.
Dependencies are inferred from the claim text.